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Acquisition of truncating mutations in the adenomatous polyposis coli (APC) protein underlies the progression of the majority of
sporadic and familial colorectal cancers. As such, the localisation patterns and interacting partners of APC have been extensively
studied in a range of systems, relying on the use of a broad panel of antibodies. Until recently, antibodies to APC have been used
largely unchecked. However, several recent reports have been invaluable in clarifying the use of a number of antibodies commonly
used to detect APC. Here, we analyse the specificity of a further subset of antibodies to APC. We used a panel of six commercially
available antibodies (directed to the amino and carboxy termini of APC) and confirm the detection of full-length APC by
immunoblotting. We demonstrate that a 150 kDa protein, also reproducibly detected by this panel of antibodies, is unlikely to be
APC. We present data for the immunological staining patterns of the APC antibodies and validate the results through RNAi. Using
this approach, we confirm that the apical staining pattern, observed by immunofluorescence and previously reported in cell systems,
is unlikely to be APC. Finally, we present our data as a summary of APC-antibody specificities for APC.
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Adenomatous polyposis coli (APC) is a large multifunctional
tumour suppressor protein that has critical functions in both
development and the normal functioning of adult cells (Joslyn et al,
1991; Kinzler et al, 1991; Miyoshi et al, 1992). Germ-line mutations
in APC cause the disease known as familial adenomatous
polyposis, where the affected individual accumulates hundreds of
polyps in the colon during the second and third decades of life
(Polakis, 1997). Such a condition predisposes the sufferer to
colorectal carcinomas. Somatic mutations in APC underlie the
majority of cases of sporadic colorectal cancers. The majority of
mutations occurring in sporadic tumours are found in an area
known as the mutation cluster region (MCR) corresponding to
amino acids 1284–1580 (Miyoshi et al, 1992). One critical tumour-
suppressor function of APC is thought to reside in the sequences
downstream of the MCR. Truncating mutations in APC result in an
inability to downregulate the activity of the oncogene b-catenin,
allowing activation of wnt-signaling pathway targets (Fodde et al,
2001).
Localisation studies of proteins are important indicators of
function. Full-length APC has been shown to be localised along the
lateral plasma membrane in mouse epithelial cells (Miyashiro et al,
1995) and, more recently, in polarised cultured epithelial cells
(Rosin-Arbesfeld et al, 2001). The latter localisation was shown to
be dependent on an intact actin cytoskeletal network. Localisation
of full-length APC is also very prominent in basal most regions,
where it is present in clusters, dependent on intact microtubules
(Rosin-Arbesfeld et al, 2001; Mogensen et al, 2002). A recent study
showed that both full-length and truncated APC are present in the
cytoplasm and that previous contradicting reports had been the
result of aberrant antibody specificities. (Brocardo et al, 2005).
The latter report (amongst others) highlights the importance of
confirming the detection specificities of antibodies to APC.
In addition to full-length protein, many different forms of APC
are known to exist within a cell as a result of alternative splicing,
post-translational modifications and degradation (reviewed by
Polakis, 1997). Functionally distinct pools of APC have been
reported with the suggestion that some pools may have a function
other than degradation of b-catenin (Reinacher-Schick and
Gumbiner, 2001; Penman et al, 2005). In general, two distinct
pools of intracellular APC are envisaged, one microtubule-bound
and found at membrane protrusions and the other plasma
membrane bound in an actin-dependent manner (Nathke et al,
1996; Rosin-Arbesfeld et al, 2001; Mogensen et al, 2002). A large
multifunctional protein such as APC is an excellent candidate for
the existence of functional variants with different roles in various
tissues, stages of development and physiological states.
Furthermore, a number of studies have found APC to be
localised apically with a range of independent antibodies directed
to both the amino and carboxy terminus of APC in a variety of
different cell lines and human and mouse tissues, including normal
colon and colorectal tumours (Miyashiro et al, 1995; Senda et al,
1996; Midgley et al, 1997; Reinacher-Schick and Gumbiner 2001;
Anderson et al, 2002; Umar et al, 2005) (see Table 1b).
We therefore set out initially to analyse a protein band
(150kDa), which was detected by a panel of antibodies directed
to the N and C termini of APC on Western blots of cell lysates from
a number of colorectal cancer cell lines. As, for any cell line, it is
always desirable to use at least two different antibodies to validate
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sdata, these Western blot data might have appeared to be
convincing. However, on further analysis, it seemed unlikely that
this protein was APC. We report these findings and present a
summary of the antibody specificities for the panel of commonly
used antibodies to APC. This study supports and expands on the
recent study by Brocardo et al (2005) and includes commonly used
antibodies to APC that were not tested in their study. The
relevance of reporting such antibody specificities lies in the central
importance of APC to cancer development.
MATERIALS AND METHODS
Cell lines
SW480 cells (ECACC, and gift from MRC laboratories, Leicester,
UK) were grown in DMEM/10%FBS, HCT116 cells (ECACC) were
grown in McCoy’s 5a medium/10%FBS, HEK293 cells (ECACC)
were grown in MEM/10%FBS. All cells were grown at 371C with 5%
CO2.
Immunoprecipitation and Western blot
Cells for immunoprecipitation (IP) and Western blot were
collected by scraping, resuspended in IP buffer (50mM Tris-HCl
(pH 7.4), 200mM KAc, 0.5% Triton-X-100, 1mM AEBSF, 10mM
E-64, 2mgml
 1 aprotinin, 1mM pepstatin, 10mM bestatin, 100mM
leupeptin, 1mM sodium ortho-vanadate) and lysed in a FastPrep
FP120. Lysates were then centrifuged at 20000g at 41C for 20min.
For IP, supernatants were incubated with 20mgml
 1 antibody or
normal IgG at 41C for 2–3h. Protein G linked to agarose beads was
pre-blocked for 1h in 3% milk and incubated with lysates for 1h.
Protein G beads were then washed three times in IP buffer.
Immunoprecipitates were run on 7.5% SDS–PAGE gels and
transferred to PVDF membrane in 2  Towbin buffer with
0.02% SDS or CAPS with 10% methanol at 600mA overnight.
For whole-cell lysate, Western blots Laemmli buffer was added to
whole-cell lysates, immediately following lysis and centrifugation
and SDS—PAGE, and transfer carried out as above. Blots were
probed with antibodies as follows: APC(Ab2), APC(Ab5), AP-
C(Ab6) 1:100 (Calbiochem, Nottingham, UK); APC(H-290)
1:2000 (Santa-Cruz Biotechnology Inc., Heidelberg, Germany);
APC(Ab120) 1:2500 (AbCam, Cambridge, UK); aTubulin 1:10000
(Sigma, Dorset, UK). Bands were quantified using QuantityOne
(BioRad Laboratories Ltd., Hertfordshire, UK).
Immunofluorescence
Cells were grown to confluence in 40mm tissue culture dishes, or
in on glass coverslips in 24-well plates for RNAi. Cells were fixed in
4% paraformaldehyde for 20min, permeabilised with 0.2% Triton-
X-100 for 15min and blocked in PBS-5% FBS for 1h at room
temperature. Cells were incubated with primary antibodies Ab4
1:50 (Oncogene), Ab5 1:50, Ab6 1:50 (Oncogene), Ab120 1:100
(AbCam), Ali12–28 1:250 (Millipore, Watford, UK), b-catenin
(E-5) 1:100 (Santa-Cruz) for 30–60min at 371C then washed three
times in PBS. Cells were then incubated in secondary antibody
(AlexaFluor 488 or 568 anti-mouse 1:400 (Molecular Probes,
Paisley, UK), AlexaFluor 488 or 568 anti-rabbit) for 30–60min at
371C and again washed three times in PBS. Cells were imaged using
a Carl Zeiss Axioplan2 LSM510 confocal microscope.
RNAi
Cells were grown in six-well plates for Western blot and on glass
coverslips in 24-well plates for immunofluorescence (IF). Cells
were grown in normal media for 2 days then transfected with
either APC siRNA or a non-interfering control using RNAifect
(Qiagen, Crawley, UK). After approximately 16h, cells were
washed with PBS and fresh medium added. Cells were used for
either IF or Western blot 48h after transfection. The DNA target
for APCe2 was 50-TATGGCTTCTTCTGGACAGAT-30 (within exon
2 of APC), APCc2 was 50-AATCGCCTGAACTCCTTTATT-30.
The control non-interfering siRNA’s DNA target sequence was
Table 1b Summary of other APC antibodies reported to detect apical staining
Antibody Reference Epitope Apical staining
APC-C-ter Miyashiro et al (1995) C-terminal 14aa Apical staining in mouse duodenum, proximal and distal colon
APC-C-ter Senda et al (1996) C-terminal 14aa Lateral and apical cytoplasm in mouse colon
APC 3122 Midgley et al (1997) N-terminal 8–347aa Apical staining in a variety of human tissue sections
APC 3161 Midgley et al (1997) C-terminal 2813–827aa Apical staining in a variety of human tissue sections
APC N-15 Reinacher-Schick and
Gumbiner (2001)
N-terminal 2–16aa Apical staining in a variety of cell lines and mouse colon
Variety of N- and C-terminal
APC antibodies
Anderson et al (2002) — Apical staining in normal colon, polyp and carcinoma with a
variety of antibodies
APC Ab7 Umar et al (2005) N-terminal 1–226aa Apical in transmissible murine colonic hyperplasia
APC Ob Umar et al (2005) N-terminal Apical in transmissible murine colonic hyperplasia
APC F-3 Umar et al (2005) N-terminal 2–289aa Apical in transmissible murine colonic hyperplasia, and weak
apical staining at the base of normal crypts
Table 1a Summary of APC antibodies that detect apical protein and/or 150-kDa protein
Antibody Clone no. / ID no. Epitope Localisation Western blot
APC (Ab2) IE1 C-term 300aa — Full length, 150kDa
APC (Ab4) HG2 C-term 300aa Apical/cytoplasmic Fails to detect APC
APC (Ab5) CF11 N-term 60–73aa Apical/cytoplasmic
a Full length, truncated, 150kDa
APC (Ab6) DB1 C-term 300aa Apical/cytoplasmic Full length, 150kDa
APC (Ab120) c-APC 28.9 C-term 300aa Apical/cytoplasmic Full length, 150kDa
APC (H-290) H-290 N-term 1–289aa Cytoplasmic Full length, truncated, 150kDa
APC (N-15) N-15 N-term 2–16aa Apical/cytoplasmic Fails to detect APC
aWe did note some batch variation with this antibody, with not all batches detecting apical protein.
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control, an APC siRNA, which failed to reduce the levels of APC in
the cells was used. The DNA target for this siRNA, APCc1, was
50-GTCCTGTATCAGAGACTAAT-30. APCc1 and APCc2 are within
the region corresponding to the last 300 amino acids at the C
terminus of APC. The Qiagen validated siRNA, Hs_APC_6, was also
used; for this siRNA, HiPerFect (Qiagen) was used for transfection.
Cells were grown in normal media for 24h before transfection,
and were used for Western blot and IF 48h after transfection.
Non-interfering siRNA controls were carried out alongside.
RESULTS
Detection of a 150-kDa immunoreactive protein in
epithelial cells using a panel of antibodies to APC
We used a panel of antibodies directed to the N and C termini of
APC in Western blotting experiments on whole-cell extracts, to
determine the size of APC present in a range of cultured cell lines
and to confirm that the same protein sizes were detected by all the
antibodies. The antibodies used, and the amino-acid regions to
which they were raised are shown in Figure 1 and Table 1a,b. The
cell lines HCT116 (colorectal cancer cell line) and HEK293 (Human
embryonic kidney) both express full-length APC (314kDa),
whereas SW480 expresses a truncated APC, whose predicted size
is 147kDa, but actual running size is 152–155kDa. Western
analysis showed that a band representing full-length APC was
detected at 314kDa by all antibodies used (Ab5, H-290, Ab2, Ab6,
Ab120) (Figure 2A-E). Ab4 fails to detect full-length APC on
Western blot (data not shown); however, this antibody is not
recommended by the manufacturer for use in immunoblotting.
N-terminal antibodies detected truncated APC in SW480 cells at
150kDa (Figure 2D,E). In addition, we also observed a further
band that migrated to around 150kDa, which was detected using
all the antibodies directed to both the N and the C termini of APC
(Figure 2A-E) (although this protein migrated to a size of 150kDa,
we estimate the actual size of this protein to be slightly less than
this, as it is slightly smaller than the truncated APC expressed
by SW480 cells whose predicted size is 147kDa). That a 150kDa
protein was detected by C-terminal antibodies to APC is
surprising, as SW480 has a mutation causing a truncation at
1338 amino acids, eliminating the expression of C-terminal
sequences from full-length APC (We used two different sources
of SW480 cells with the same result (data not shown).
Furthermore, sequencing across the mutated region of genomic
DNA derived from SW480 cells revealed that the expected
mutation was present (data not shown)).
We then carried out IP and Western blot with a number of APC
antibodies to test whether different antibodies would detect the
same 150-kDa protein. Both N- and C-terminal antibodies were
used for IP and products from the IP reactions were then
immunoblotted against Ab5 or H-290 (N-terminal) antibodies. In
all lanes containing antibody to APC following Western blotting, a
band was observed at 150kDa, suggesting that the C- and N-
terminal APC antibodies tested each recognise the same species of
150kDa (Figure 2F-H). Immunoprecipitation and Western blot
with N-terminal antibodies in SW480 gave a band at 150kDa,
which was the truncated APC expressed in this cell line (Figure
2F,H). Immunoprecipitation with both N- and C-terminal
antibodies and Western blot in HCT116 gave a band at the
expected size for full-length APC on longer exposures (data not
shown). In total, for the immunoblotting analysis, we used four
independently derived monoclonal antibodies to APC (Ab2, Ab5,
Ab6 and Ab120) and one polyclonal antibody to APC (H-290).
Immunofluorescence staining patterns of APC-antibodies
Ab5, Ab4, Ab6 and Ab120
After many conflicting reports, it has recently been shown
(through a combination of Western blotting, siRNA and IF) that
endogenous full-length and truncated APC is predominantly
located in the cytoplasm (Brocardo et al, 2005). Our panel of
antibodies included commonly used antibodies to APC that were
not tested in the study by Brocardo and co-workers. We used
confocal microscopy and IF localisation with our panel of N- and
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Figure 2 Multiple APC antibodies detect a band at 150kDa on Western
blot as well as detecting full-length and/or truncated APC. The N-terminal
antibodies, Ab5 and H-290 (D,E) detect full-length, truncated APC in
SW480 and an additional band at 150kDa. The C-terminal antibodies
detect full–length, but not truncated APC (A–C) and an additional band
at 150kDa. Immunoprecipitation and Western blot demonstrates that
many of these antibodies are detecting the same protein at around
150kDa (F–H). Full-length APC in HCT116 is not visible in (G), but could
be seen in the lysate and IP lanes but not IgG control lane on longer
exposures (data not shown). Although all these antibodies detect multiple
bands in addition to APC, the band at 150kDa is the only one that is
recognised by multiple APC antibodies.
Oligomerization domain
1
2 MCR 3
EB1 binding
DLG binding
APC antibodies
1. H-290
2. Ab5
3. Ab2, Ab4, Ab6, Ab120
Armadillo repeat region
15aa repeats
20aa repeats
Basic domain
Nuclear export sequence
Nuclear localization sequence
SW480 truncation
Figure 1 Positions of APC epitopes recognised by antibodies used in
this study. H-290 was raised to a peptide corresponding to amino acids (aa)
2–289 at the N terminus of APC. Ab5 has been shown to bind to aa 60–
73 (Kraus et al, 1996), which corresponds to exon 2 of APC. Ab2, Ab4,
Ab6 and Ab120 have been raised to a peptide corresponding to the last
300 aa of APC.
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sC-terminal APC antibodies to determine the localisation of protein
detected by each antibody. Confocal microscopy on confluent
HCT116 cells using the N-terminal-directed antibody to APC,
Ab5 showed predominant apical staining with fainter cytoplasmic
staining (Figure 3G,H). Similar studies using the C-terminal-
directed antibodies, Ab4, Ab6 and Ab120 demonstrate the same
staining pattern, that is, apical localisation, with fainter cytoplas-
mic staining (Figure 3A–F). We also carried out IF in the cell lines
SW480 (colon carcinoma) (Figure 3K) and HEK293 cells (human
embryonic kidney) (Figure 3I). Again, IF was carried out using
the panel of N- and C-terminal-directed APC antibodies: Ab4
(Figure 3I–K), Ab5, Ab6 and Ab120 (data not shown). Confocal
microscopy demonstrates that, in confluent HCT116 and SW480
cells, staining is predominantly localised to the apical plasma
membrane with faint cytoplasmic staining (Figure 3J,K). However,
in confluent HEK293 cells, in addition to the apical membrane
staining, we also observed lateral membrane staining, and
occasionally, some cells were observed with staining in basal
membrane regions (Figure 3I).
Three of the antibodies, which detected apical protein, Ab5, Ab6
and Ab120, also detected the 150-kDa protein on a Western blot.
Ab4 detected apical protein, but failed to detect the 150-kDa
protein or full-length APC by Western blot. H-290 did not detect
apical protein on IF, but did detect the 150-kDa protein. Ab2 did
not give any staining above background levels on IF, but did detect
the 150-kDa protein on a Western blot.
The staining patterns observed using these antibodies are not in
accordance with the observations of Brocardo et al (2005).
Furthermore, that the C-terminal APC antibodies should give the
same staining pattern as the N-terminal antibodies to APC in
SW480 cells was unusual, as C-terminal APC sequences should not
be expressed in these cells. We therefore followed this up with
siRNA to APC to determine the specificity of these antibodies to
APC. In addition, to confirm that we could detect cytoplasmic APC
using an antibody shown to be specific for APC, we also used the
antibody Ali12-28 for IF in all the cell lines. Using this antibody,
we were able to confirm that this showed cytoplasmic staining as
expected (Figure 3L).
siRNA to confirm the specificity of the antibodies
siRNAs were designed to exon 2 and to a region within the last 300
amino acids of the C terminus of APC. A commercially available
and validated siRNA to APC, Hs_APC_6 (Qiagen), was also used.
Transient transfection of the different siRNAs was carried out to
allow knockdown of gene expression for an optimised time period
of 48h in SW480 and HCT116 cells. Specific siRNA knockdown
of protein detected by antibodies to APC was compared to cells
treated with a non-interfering RNA and to untreated cells.
Whole-cell lysates were prepared from SW480 cells and the
products run on a gel and immunoblotted using antibodies that
would detect only the 150-kDa protein (C-terminal-directed
antibodies), and antibodies that would detect both truncated
APC and the 150-kDa protein (N-terminal-directed antibodies).
Three to four repeats were carried out for each siRNA. Both the
siRNA directed to exon 2, APCe2, and one of the siRNAs directed
to the last 300 amino acids of APC, APCc2, were shown to be able
to knock down truncated APC in SW480 (Figure 4A,C). One of the
siRNAs designed to the last 300 amino acids of APC, APCc1, failed
to knock down APC and was used as an additional negative control
in these experiments. Ab2, a C-terminal antibody, detects two
proteins of around 150kDa in SW480 and other cell lines, the
larger of which appears to be the same size as the 150kDa bands
detected by other APC antibodies. Neither of these proteins was
knocked down by APC siRNA directed to exon 2 and the last 300
amino acids of APC, under the conditions used here (Figure
4B,E,F).
When SW480 lysates were run on 5% SDS–PAGE and
immunoblotted against the APC antibody, Ab6 (a C-terminal
antibody), the band detected at 150kDa was resolved into several
bands (Figure 4G). None of these bands were downregulated by
APC siRNA under the conditions used here. Western blot with
Ab6 Ab120 Ab4 Ab5
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Figure 3 APC antibodies Ab6, Ab120, Ab4 (C-terminal) and Ab5 (N-terminal) all detect an apical protein in HCT116 (A,C,E,G), with some more faint
cytoplasmic staining (B,D,F,H). Ab4 shows localisation to the apical, lateral and occasionally basal membranes in HEK293, but gives an apical localisation with
more faint cytoplasmic staining in the colorectal cancer cell lines HCT116 (J) and SW480 (K). (I,J,K) show side views of the cells (projection of confocal
Z-stack). Ali12-28 gives a cytoplasmic localisation (L).
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sAb5, an N-terminal antibody which detects the truncated APC
expressed in SW480 cells, confirmed that the RNAi was successful
(Figure 4H).
RNAi with an APC siRNA directed to exon 2 of APC in HCT116
failed to knock down the 150-kDa protein detected by H-290, an
N-terminal antibody, under the conditions used here. Full-length
APC was successfully knocked down in these cells (Figure 4J).
To test whether the apical protein detected by many of these
antibodies could be knocked down by siRNAs directed to APC,
RNAi and IF staining was carried out in HCT116 cells. Both side
views (projection of a confocal Z-stack) (panels A–F, K–N) and an
apical slice (panels G,H) are shown in Figure 5. No reduction in
apical staining in cells transfected with two different APC siRNAs
was seen with both APC antibodies, Ab4 and Ab120, under the
conditions used here. To confirm successful knockdown of APC in
HCT116 cell lysates from the same batch of cells, lysates were
immunoblotted against the APC antibody Ali12-28 (Figure 5I) or
H-290 (Figure 5O). This showed successful knockdown of APC.
APC antibody specificity summary
Table 1a,b is presented as a summary table, showing data for the
specificity of the APC antibodies in this and other studies. We
summarise their activity in (i) Western analysis (detection of a 314
and 150kDa band) and (ii) their corresponding immunostaining
patterns (if the antibody is suitable for both applications). We have
also presented published data from other laboratories to provide a
comprehensive summary table of APC antibody specificities.
DISCUSSION
The specific detection of APC is of paramount importance due to
its central role as a tumour suppressor protein, and its ability to
result in the development of carcinomas when mutated. Here, we
describe the detection specificities of a panel of antibodies that
have been developed to detect APC. This work extends several
recent publications in this area and importantly serves to provide a
comprehensive analysis of APC antibody specificities (Roberts
et al, 2003; Brocardo et al, 2005).
Initially, we carried out Western blotting experiments, using a
panel of antibodies to APC to confirm the size of expressed APC
in a number of different cell lines. We observed a band at
approximately 150kDa with a number of antibodies in the three
different cell lines used. One possible explanation for the presence
of this band was expression of an unusual and cryptic splicing
event in exon 15 of APC. This 150-kDa protein could not have been
a post-translational modification, as it was detected by C-terminal-
directed antibodies to APC, beyond the termination codon in
SW480, in addition to it being detected with N-terminal antibodies.
We then carried out further experiments to confirm or refute this
based on validating the specificities of the antibodies used to detect
APC, as an alternative explanation for the presence of this 150-kDa
band on APC Western blots could be that several antibodies were
crossreacting with proteins of approximately the same size.
Two approaches were followed to confirm the specificity of
antibodies through (i) reciprocal co-IP and blotting experiments
and (ii) RNAi experiments. The former approach suggested the
presence of a 150-kDa cryptic splice variant of APC, or that several
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Figure 4 RNAi for APC does not reduce the levels of the 150-kDa protein. APC siRNAs APCe2 and APCc2 reduce levels of truncated APC in SW480
(A, C), but not the 150-kDa protein detected by Ab2 (B, E) or the nonspecific band below the 150kDa (F). Negative controls shown are NI (a non-
interfering control siRNA) and APCc1 (an siRNA designed to APC which failed to reduce APC levels). Tubulin loading control is shown in (D). Graphs
(A, B) show normalised data for the Western blots shown below (C–F). The 150-kDa band detected by Ab6 (C-terminal) in SW480 resolves into several
bands on 5% SDS–PAGE, none of these bands are downregulated by APC RNAi (G), Western blot with Ab5 (N-terminal) confirmed that APC had been
successfully downregulated (H), loading control is shown in (I). Full-length APC, but not the 150-kDa protein, was downregulated by APC siRNA in
HCT116 (J), tubulin loading control shown in (K).
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sAPC antibodies were all crossreacting with the same 150-kDa
protein. The latter approach suggested that the antibodies used
were likely to be detecting a protein other than APC at 150kDa, as
this 150-kDa protein could not be knocked down by APC RNAi.
The apical protein seen on IF staining with several APC antibodies
also failed to be knocked down by APC RNAi.
We considered the possibility that a cryptic splicing event
produces a variant that is more stable than ‘conventional’ APC.
The region of APC between amino acids 1034 and 1337 is
responsible for the ubiquitin-proteasome-mediated downregula-
tion of APC (Choi et al, 2004). This region also encompasses the
MCR and the truncating mutation in SW480. It remains a feasible
proposition that a cryptic splicing event at the start of exon 15 may
give rise to a form of APC that has this region spliced out, thereby,
becoming more stable and therefore not ‘knocked down’ under the
conditions used here. However, RT–PCR with primers to exons 1,2
and 3 of APC and two primers within the sequence corresponding
to the last 300 amino acids at the C terminus of APC, successfully
amplified full-length APC, but did not give any products which
would account for a spliced form of APC 150kDa in size (data not
shown). Northern blot gave a band at the expected size for full-
length APC and no smaller bands (data not shown). As no
alternatively spliced APC mRNA could be detected by either of
these methods, it seems unlikely that the 150-kDa protein we
observed could be an alternatively spliced form of APC, which is
more stable than the full-length or truncated APC proteins
expressed in the cell lines used in the RNAi experiments (Brocardo
et al (2005) looked for C-terminal splice variants of APC by
Western blotting, but did not detect bands corresponding to
potential splice variants. One antibody used in their studies, Ab4,
is not recommended for use in Western blotting and fails to detect
full-length APC (Table 1a,b), the two other C-terminal antibodies
used are not listed in our report).
Our findings with this panel of antibodies led us to further
clarify and present a summary of the specificity of the panel of
antibodies to APC that were used in this study. Many of these
antibodies are able to reliably detect full-length APC and/or
truncated APC. Of the antibodies tested by us, only Ab4 and N-15
failed to detect full-length or truncated APC. However, all the
antibodies tested, which were able to detect APC, also gave several
nonspecific bands. Five out of all the antibodies studied detect an
apical protein by IF; APC RNAi confirmed that this protein is not
likely to be APC and therefore it appears that these antibodies
cannot reliably detect conventional APC by IF staining. Validation
of the specificity of these antibodies will serve to lessen ambiguities
in the literature.
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Figure 5 No reduction in staining was seen with Ab4 after RNAi for APC with APCe2 siRNA (A–H). An apical slice from a confocal Z-stack is shown in
(G, H) and a projection of a confocal Z-stack (side view of cells) is shown in (A–F). Western blot with the APC antibody Ali12–28 shows the RNAi
successfully reduces APC levels (I), loading control shown in (J). Normalised reduction was approximately fivefold. The APC siRNA Hs_APC_6 fails to
reduce the apical staining seen with the APC antibodies Ab4 (K, L) and Ab120 (M, N). Western blot confirmed that APC levels were reduced in RNAi
treated cells (O), loading control shown in (P).
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